A phase 3 trial evaluating sotatercept-csrk (Winrevairâ„¢) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIRâ„¢ (sotatercept-csrk) Early and Move to Final ...
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...
Merck , known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background ...
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...
World Health Organization **Dr. McLaughlin is a member of the adult sotatercept steering committee, an investigator in the ZENITH and HYPERION trials and a paid consultant to Merck. The HYPERION ...
World Health Organization **Dr. McLaughlin is a member of the adult sotatercept steering committee, an investigator in the ZENITH and HYPERION trials and a paid consultant to Merck. About HYPERION The ...
MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...
The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.